In this research we describe the improvement of the water-solubility of cyclic epitope mimics based on the HCV E2 glycoprotein by incorporation of suitable polar hinges.
In this research we describe the improvement of the water-solubility of cyclic epitope mimics based on the HCV E2 glycoprotein by incorporation of suitable polar hinges.
The poor solubility of epitope mimics based on peptide sequences in the envelope (E2) protein hampered their synthesis and purification and made it very difficult to prepare the molecular constructs for evaluation of their bioactivity. Since changes in the amino acid composition are hardly possible in these epitope mimics in order to increase water-solubility, a polar cyclization hinge may offer a remedy leading to a significant increase of polarity and therefore water solubility. These polar hinges were applied in the synthesis of better water-soluble HCV-E2 epitopes. An azide functionality in the polar hinges allowed attachment of a tetraethylene glycol linker by Cu-catalyzed azide-alkyne cyclo-addition (CuAAC) for a convenient conjugation to ELISA plates in order to evaluate the bio-activity of the epitope mimics. The immunoassays showed that the use of more polar cyclization hinges still supported anti-HCV antibody recognition and did not negatively influence their binding. This significantly increased solubility induced by polar hinges should therefore allow for the molecular construction and ultimate evaluation of synthetic vaccine molecules.
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| INTRODUCTION
The rapidly increasing therapeutic potential of cyclic peptides is due to multiple favourable molecular attributes. 25 These attributes include the ability to access large and often flat surface areas within protein binding sites, thereby achieving high-selectivity and binding-affinity.
Furthermore, peptide cyclization improves its proteolytic stability compared to the linear peptide. Earlier, we have shown that cyclic peptides therefore might be especially attractive in the molecular construction of epitope mimics. 17, 29 Moreover, it was recently found that cyclic peptides were better epitope mimics than the linear, non-cyclized compounds. 17, 29 As part of our efforts directed towards synthetic vaccines we have been especially interested in HIV-gp120 and the HCV-E2. 21, 29 Presently the focus is on HCV, which is a rapidly mutating and highly diverse virus. The natural immune response to this virus often falls short due to various immune evasive strategies and hypervariable immunogenic decoy domains of the virus that do not impede its viral efficiency. 1, 18, 19, 22 In essence, the immune system of the host is exhausting itself by targeting ineffective viral epitopes.
Despite enormous efforts, no vaccine is available as yet against HCV. 20 An approach to remedy this might be selection of effective and conserved epitopes, which could be mimicked by cyclic peptides and thereby, circumvent problems with immunogenic decoys and inefficient epitopes. 23 Multiple cyclic peptides were considered based on promising neutralizing epitopes located within the CD81 binding site of the HCV E2 glycoprotein. This binding site consists of 4 epitope domains (Epitopes I, II, III, and IV) to which various antibodies have been generated and isolated that bind these epitopes individually (continuous) or as parts of a larger domain (discontinuous). 24 Their therapeutic potential is based on these antibodies being capable of neutralizing HCV infection by blocking the CD81 binding site of the E2 glycoprotein. 2, 8, 26 Epitopes II and IV were found to bind the same class of HC84 antibodies. 8, 24 Recently, we have shown that antibody HC84.1 binds our previously developed epitope II mimic without parts of epitope IV. 17 Therefore, in this study we have focused on epitopes I, II, and III.
One of the most attractive cyclization methods, presently available is based on thioether-formation with cysteine-containing peptides. Electrophilic bromide (for example benzylic-bromide) derivatives and Michael acceptors (Figure 1 ), among others, have been applied in the synthesis of many diverse (bi)cyclic peptides also towards synthetic vaccines. [3] [4] [5] [9] [10] [11] 14, 15, 17, [27] [28] [29] However, depending on the sequence, the solubility of cyclized peptides onto a benzylic core (i.e. TBMB) or derivatives thereof can be very poor. Poor water-solubility may hamper purification of cyclized peptides using reverse phase chromatography, resulting in very low yields thereby also limiting their therapeutic potential. In general, poor water-solubility of peptides is often responsible for a large attrition rate similar to that observed in the small molecule drug discovery process. 6 Several hinges with increasing polarity for cyclization of peptides have been described in the literature to improve the water solubility of resulting molecular constructs. [3] [4] [5] [9] [10] [11] [12] 15, 16, 27 Examples of such polar hinges are shown in Figure 1 and include the 2,4,6-1,3,5triacryloyl-1,3,5-triazinane (TATA), N,N 0 ,N 00 -(benzene-1,3,5-triyl)-tris (2-bromoacetamide) (TBAB) and N,N 0 ,N 00 -benzene-1,3,5-triyltrisprop-2-enamide (TAAB) tris (bromomethyl)-s-triazine (TBMT) and 1,1 0 ,1 00 -(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone) (TATB) cyclization hinges. 9, 12, 16 Especially, the latter two, recently developed by us, have shown to be beneficial for the aqueous solubility of cyclic peptides. 16 Recently, Heinis et al. have described a phage display protocol with respect to high-throughput screening of bicyclic peptides, thereby opening up a wide range of potential therapeutics. 4 Interestingly, they found that different hinge structures (i.e. TBMT, TATA, TBAB, and TAAB) incorporated into bicyclic peptides resulted in different conformations of the bicyclized peptide. 9 Moreover, changing the cyclization hinge on a promising isolated sequence from the phage display library could reduce or even completely abolish (binding) activity. 3, 9, 27 In addition, depending on the used cyclization hinge, different peptide consensus sequences were isolated from the phage display library. 27 Taken together, this suggested that the core structure of the cyclization hinges does have a significant impact on the overall structure of the cyclized peptide.
The main goal of the work reported here focussed on the improvement of the water-solubility of cyclic epitope mimics based on the HCV E2 glycoprotein by incorporation of suitable polar hinges.
The poor solubility of the peptide sequences corresponding with these epitopes hampered the synthesis and purification of the epitope mimics, and made it very difficult to prepare the molecular construct for evaluation of their bioactivity. Evidently, possibilities to change amino acids in these epitope mimics in order to increase watersolubility are very limited, as their peptide sequences have to resemble the mimicked peptide segments of the epitopes as closely as possible. Recently, we have addressed the issue of poor solubility of peptide loops for attachment to our molecular (TAC) scaffolds by development of polar hinges, which upon incorporation led to a significant increase of polarity and therefore their water solubility. Therefore, we wished to apply these polar hinges in the synthesis of better F I G U R E 1 Chemical structures of cyclization hinges for preparation of bicyclic peptides 1,3,5-tris (bromomethyl)benzene (TBMB) (A); 1,3,5-triacryloyl-1,3,5-triazinane (TATA), N,N 0 ,N 00 -(benzene-1,3,5-triyl)tris(2-bromoacetamide) (TBAB) and N,N 0 ,N 00 -benzene-1,3,5-triyltrisprop-2-enamide (TAAB) described by Chen et al. 9 and Rim et al. 12 (B); and 2,4,6-tris (bromomethyl)-s-triazine (TBMT) and 1,1 0 ,1 00 -(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone) (TATB) described by Van de Langemheen et al. 16 (C) water-soluble HCV-E2 epitopes. Here, we describe the preparation of cyclized synthetic peptide sequences onto various cyclization (polar) hinges, equipped with a functional azide handle. 16 In addition, an alkyne-functionalized linker equipped with a trityl-protected thiol moiety is described that allowed for conjugation of cyclic peptides with different core structures via by Cu-catalyzed azide-alkyne cycloaddition (CuAAC). Upon deprotection of the thiol-moiety, the resulting epitope mimics were readily conjugated to a maleimide-activated surface and their bio-activity was evaluated by ELISA ( Figure 2 ).
| MATERIALS AND METHODS

| General
All reagents and solvents were used as received. Fmoc-amino acids were obtained from Activotec (Cambridge, United Kingdom) and N,N,N 0 ,N 0 -Tetramethyl-O- (6- These syntheses were carried out as described by van de Langemheen et al. 16 F I G U R E 2 Thiol-maleimide conjugation of epitope mimics forming a plate-surface with uniformly oriented peptides used for ELISA to evaluate epitope mimicry 2.2.2 | 1-(azidomethyl)-3,5-bis (bromomethyl)-striazine 1, azido triazinane-tris(2-bromoethanone) 2, and 1-(azidomethyl)-3,5-bis (bromomethyl)benzene 3
These syntheses were carried out as described by van de Langemheen et al. 16 
| Cyclization linker 4
These syntheses were carried out as described by van de Meuleman et al. 17 
| Tetraethylene glycol mono-trityl thioether 5
These syntheses were carried out as described earlier by Meuleman et al. 17 
| Alkyne functionalized tetraethylene glycol monotrityl thioether 6
All steps were performed under N 2 atmosphere. Tetraethylene glycol monotrityl thioether 5 (2.42 g, 5.3 mmol; 1.0 equiv.) was dissolved in dry THF (150 ml). The resulting solution was cooled to 0 C using an ice bath, followed by addition of sodium hydride (60% dispersion in mineral oil, 0.32 g, 8.0 mmol; 1.5 equiv.). The resulting reaction mixture was stirred for 1 hour at 0 C. After which, propargyl bromide (80 wt.% in toluene, 770 μl, 6.9 mmol; 1.3 equiv.) was added to the reaction mixture. The ice bath was removed and the reaction mixture was stirred for 1 day at RT, after which the reaction had not achieved complete conversion as yet according to TLC (EtOAc). Nevertheless, solvent was removed in vacuo and the residue was taken up in CH 2 Cl 2 (100 ml). The resulting sodium bromide precipitate was filtered off 
| Peptide 7
This peptide was synthesized as described above by solid phase synthesis on a 0.25 mmol scale, which afforded crude peptide (384.0 mg).
The crude peptide was used in the cyclization by alkylation step. 
| Peptide 8
This peptide was synthesized as described above by solid phase synthesis on a 0.25 mmol scale, which afforded crude peptide (401.0 mg).
| Peptide 9
This peptide was synthesized as described above by solid phase synthesis on a 0.25 mmol scale, which afforded crude peptide (354.2 mg).
| Peptide 10
This peptide was synthesized as described above by solid phase synthesis on a 0.25 mmol scale, which afforded crude peptide (400.4 mg).
| General method for peptide cyclization
| Epitope mimics 34-37
Removal of the Trityl group was performed using TFA:H 2 O:TIS:EDT (90:5:2.5:2.5, v/v/v/v) (1 ml) for 15 minutes at room temperature, affording the free-thiol moiety. Then, the product was precipitated in Et 2 O (15 ml) and collected by centrifugation (4500 rpm; 5 min). The collected precipitate was washed twice using Et 2 O (15 ml), followed by centrifugation (4500 rpm; 5 min). After which, the precipitate was dissolved in tBuOH:H 2 O (1:1, v/v) and lyophylized, which afforded the crude epitope mimics. The crude product was dissolved in HPLC buffer and the resulting solution was clarified by centrifugation (4500 rpm; 5 min), after which, the compound in the supernatant was purified by preparative HPLC.
| Cyclic peptide 11
Peptide 7 (47.0 mg, 25.1 μmol; 1.0 equiv.) was treated with 1-(azidomethyl)-3,5-bis (bromomethyl)-s-triazine 1 (12.1 mg, 37.6 μmol; 1.5 equiv.) in DMF/H2O as described above. The obtained crude product (54.5 mg) was dissolved in 6 mL buffer A and purified as two batches of 3 mL: 100% buffer A for 5 min followed by a linear gradient of buffer B into buffer A (0-40%) over 40 min at a flow rate of 12. 
| Cyclic peptide 21
| Epitope mimic 23
Cyclic peptide 11 (5.3 mg, 2.6 μmol) and linker 6 (5.0 mg, 10.2 μmol; dissolved in 355 μl DMF of which 100 μl was used) was subjected to 
| Epitope mimic 24
| Epitope mimic 25
Cyclic peptide 13 (3.7 mg, 1.8 μmol) and linker 6 (4.6 mg, 9.4 μmol; 
| Epitope mimic 26
| Epitope mimic 35
Crude peptide 8 (46.2 mg, 25.0 μmol; 1.0 equiv.) was treated with our previously developed cyclization linker 4 3 (27.3 mg, 37.5 μmol; 1.5 equiv.) as described above in the general method for peptide cyclization.
The obtained crude product (53.9 mg) was dissolved as three batches of 10-20 mg in 3 mL buffer A:B 
| Epitope mimic 36
Crude peptide 9 (48.8 mg, 25.7 μmol; 1.0 equiv.) was treated with our previously developed cyclization linker 4 3 (28.0 mg, 38.4 μmol; 1.5 equiv.) as described above in the general method for peptide cyclization. 
| Monoclonal antibodies
The Mabs AP33 13 , HC84.1 8 , and DAO5 31 used in this work were previously described. 
| Immobilisation method and ELISA
| RESULTS AND DISCUSSION
Thus, in order to improve the water-solubility of the recently developed cyclic and linear epitope HCV-E2 mimics equipped with a TEG spacer for binding to a surface using maleimide-thiol conjugation, 17 we have incorporated our more polar cyclization hinges 1 and 2 (Figure 3 ) 16 in addition to our previously used benzyl-derivative 3. 17 Instead of installing the different cyclization hinges on our previously developed TEG spacer directly, as was earlier described for the bis-benzyl bromide hinge 4, we decided to opt for a more modular approach. The peptides were cyclized onto the hinges first, followed by CuAAC to install the S- Next, the required dicysteine containing peptides were obtained by solid phase peptide synthesis ( 9) . Epitope I is a flexible broadly neutralizing immunogenic domain S C H E M E 2 Cyclization of precursor peptides 7-10 with azido cyclization hinges DBMT-N 3 1, TADB-N 3 2, and DBMB-N 3 3. The reported yields are of purified products, after preparative reverse phase HPLC recognized by neutralizing antibody (Nab) AP33 (Table 1) . 7, 13, 30 Epitope II is a broadly neutralizing immunogenic domain recognized by Nab HC84.1 ( Table 1 ). 8 Particularly, broadly neutralizing antibodies AP33 13 and HC84.1 8 are of special interest as they have been found to neutralize HCV pseudo-particles (HCVpp) carrying E2 glycoprotein of various genotypes, indicating that these are highly conserved epitopes in an otherwise rapidly mutating virus. Epitope III is an immunogenic domain of interest, as together with epitopes I and II it is located in the CD81 binding site of the viral E2 glycoprotein. 31 A sequence within epitope III is recognized by non-neutralizing antibody DAO5 (Table 1) , 31 which despite being non-neutralizing will still allow us to validate the conformation of our epitope mimics. In addition, a scrambled peptide sequence 10 was synthesized based on the epitope II region as a negative control. and was not part of the epitope sequence. 24 CuAAC is a widely used and highly versatile conjugation method of an azide and alkyne moiety. 32 Typically, the reaction can be con- 10 As a consequence we were interested in verifying the use of alternative azide-functionalized cyclization hinges and study their impact on antibody binding. To investigate whether different cyclization hinges support the desired conformation of synthetic peptides based on promising HCV E2 epitopes for antibody binding we decided to employ our previously described ELISA screen. 17 In order to compare the obtained results we wanted to include epitope mimics 34-37 ( Figure 5 ) based on our previously reported cyclization linker 4 (Figure 3 ). 17 Since these previously studied epitope mimics had not been obtained by CuAAC and therefore did not contain a triazole moiety, we had wished to include the corresponding epitope mimics 25, 28, and 33 containing a triazole moiety for comparison of their bio-activity monitored by ELISA. Nevertheless, we did not expect a significant influence of the triazole moiety, because of its distance from the epitope sequence. Unfortunately, any effect of the triazole moiety could not be studied because epitope mimics 25, 28, and 33 were not obtained in sufficient yields (Scheme 3). The inability of obtaining these epitopes containing the hydrophobic TBMB hinge underlines the importance of having a hinge with improved solubility properties thereby providing better access to the said epitopes.
Cyclization of dicysteine peptides with different hinges DBMT-
Epitope mimics 23, 24, 26, 27, 30, 34, 35 , and 36, as well as the scrambled negative controls 31, 32, and 37 (Scheme 3 and Figure 5) were covalently immobilized on Pierce ® maleimide activated 96-well plates by maleimide-thiol conjugation. Subsequently, the resulting immobilized epitope mimics and scrambled negative controls were evaluated for antibody binding by ELISA. 17 The immobilized epitope I mimics 23, 24, and 34 were evaluated in the ELISA against Nab AP33 ( Figure 6 ). Immobilized epitope mimic 24 compared excellently to epitope mimic 34 towards binding of antibody Nab AP33. In addition, immobilized epitope mimic 23 showed excellent binding of Nab AP33. However, the immobilized scrambled loop 31, serving as a negative control, showed some unexpected binding of Nab AP33 that was not observed for immobilized scrambled negative controls 32 and 37 ( Figure 6 ). This suggests that the DBMT-N 3 1 polar hinge causes indirect binding to Nab AP33 and would be unsuitable for developing an epitope I mimic.
Immobilized loop II mimics 26, 27, and 35 were evaluated for binding of Nab HC84.1 (Figure 7 ). Both immobilized epitope mimics and 36, and no binding of immobilized scrambled negative controls 32
and 37 was observed of this antibody.
| CONCLUSIONS
In conclusion, utilizing more polar cyclization hinges did improve the water-solubility of cyclic peptides. Higher yields were obtained for peptides cyclized on DBMT-N 3 1 and TADB-N 3 2 cyclization hinges compared to both DBMB-N 3 3 (Figure 3 ) and our previously reported hinge without the presence of a triazole ring (compound 4, Figure 3 ). 17 As a consequence higher concentrations of compound could be dissolved in the buffer system for purification by preparative HPLC. In addition, analytical HPLC showed shorter retention times for DBMT-N 3 1 and TADB-N 3 2, indicating an increased polarity and likely an improved water-solubility of the resulting cyclic peptides. The latter was confirmed by a solubility experiment. Heinis et al. showed that using different cyclization hinges have a significant influence on the conformation of the resulting (bi)cyclic peptides. 3, 4, 9, 10, 27 However, the epitope mimics reported here did not show any difference with respect to antibody binding as indicated by ELISA for the different cyclization hinges used. This does not in anyway indicate that the different cyclization hinges do not induce conformational changes, but in view of the size of rings of the cyclic peptides, this may not be 'detected' by the antibody. It is known that the HCV E2 glycoprotein is a flexible protein, adopting multiple different conformations, and this may be reflected in the individual peptide epitopes. This dynamic nature of the viral protein may be one of the major hurdles that hinder the development of a therapeutic vaccine against HCV. 7.30.34 Nevertheless, our epitope mimics significantly benefit from the use of more polar cyclization hinges, with respect to water-solubility, facilitating their purification and evaluation without compromising their ability for antibody binding.
